The potential of a pseudorabies virus (PRV) nucleocapsid protein (NC)-based enzyme-linked immunosorbent assay (ELISA) as a screening assay for PRV infection in subunit-vaccinated and nonvaccinated pigs was studied. The NC-ELISA compared favorably to a commercial ELISA for detecting PRV infection in nonvaccinated pigs. Virus-specific antibody was first detected by the NC-ELISA between days 14 and 21 in 5 pigs challenged intranasally with 10 4 PFU of virus. Antibody continued to be detected in these pigs through day 42, when the experiment was terminated. The NC-ELISA also detected antibody in 23 of 24 pigs from PRV-infected herds. In contrast, the commercial ELISA detected antibody 1 week earlier than the NC-ELISA in experimentally infected pigs but failed to detect antibody in 3 naturally exposed pigs that were identified by the NC-ELISA. Infection in these animals was confirmed by radioimmunoprecipitation analysis. The potential usefulness of the NC-ELISA for detecting infection in vaccinated pigs was also evaluated. The nucleocapsidspecific antibody responses of 10 PRV envelope glycoprotein subunit-vaccinated pigs were monitored prior to and following nasal exposure to a low dose (10 2.3 PFU) of PRV. Sera were collected periodically for 113 days after infection. Nucleocapsid-specific antibody responses measured by the NC-ELISA remained below the positive threshold before challenge but increased dramatically following virus exposure. Maximum ELISA responses were obtained on day 32 postchallenge (p.c.). Mean ELISA responses decreased thereafter but remained well above the positive threshold on day 113 p.c. PRV nucleocapsid protein can be used effectively as antigen in the ELISA for detecting PRV infection in both nonvaccinated and subunit-vaccinated pigs. From the Department of Veterinary Microbiology and Preventative Medicine (McGinley, Todd, Platt), and the Iowa State Vet-test based on a single antigen preparation, as dimonerinary Diagnostic Laboratory (Hill), College of Veterinary Medi-strated by recent work using PRV nucleocapsid protine, Iowa State University, Ames, IA 50011.
Pseudorabies or Aujeszky's disease virus is an al-protein-based subunit vaccine using a differential diphaherpesvirus that causes an economically important agnostic test based on an early excreted PRV disease of swine. 3, 22 The disease is characterized by glycoprotein, gX. 10, 13 This concept is, in part, the basis acute respiratory and neurologic involvement followed of some current PRV deletion mutant vaccines. The by the establishment of latent infection. 3 Mortality following acute infection of young pigs (l-4 weeks old) ranges from 50 to 100%. 3 Mortality decreases with age; however, morbidity and latency occur following infection of older animals. 3 Current methods of disease prevention and control are centered on vaccination and serologic monitoring. Pseudorabies vaccines provide protection against acute disease but do not prevent pseudorabies virus (PRV) infection and subsequent transmission, 6-8,14,16.17,21 C urrent national PRV eradication programs underscore the need for reliable, sensitive, and specific assays to identify virus-infected pigs and differentiate them from vaccinated pigs.
Earlier work demonstrated that it was possible to differentiate between wild-type virus-i nfected and noninfected Pigs vaccinated with a PRV envelope glyco-virus strains used in these vaccines are characterized by deletions in 1 or more of the genes encoding thymidine kinase and glycoproteins gI, gp63, gIII, and gX. 1, 8, 17, 19 The deleted proteins are the basis of differential diagnostic tests. The presence or absence of antibodies to these glycoproteins makes it possible to distinguish wild-type virus infection from vaccination.
The variety of deletion-mutant vaccines available poses some problems for PRV control programs. Because each deletion-mutant vaccine requires the use of a specific diagnostic antigen, accurate vaccination records must be kept to permit selection of the appropriate differential diagnostic test. Furthermore, pigs that are initially vaccinatedw i t h 1 vaccine cannot be revaccinated with another without the possibility of inducing a false-positive reaction. These problems can be avoided with the use of PRV envelope glycoproteinbased subunit vaccines and a standardized diagnostic ated pigs 10 Because of the concerns with and approaches to PRV control and eradication, the following study was undertaken to evaluate the potential of a PRV nucleocapsid (NC) enzyme-linked immunosorbent assay (ELISA) for use as a serologic screening assay for the detection of PRV infection in nonvaccinated pigs and in pigs immunized with subunit vaccines.
Materials and methods
Virus and cell culture. Pseudorabies strain Be 15 was used for all antigen production and virus challenge experiments. Madin-Darby bovine kidney (MDBK) cells were used for virus propagation. Growth and maintenance medium consisted of Dulbecco's modified Eagle's medium (D-MEM) a supplemented with 10% and 1% heat-inactivated fetal bovine serum, b respectively.
Serum virus neutralization assay. Serum virus neutralization (SN) was performed on all serum samples as previously described. 15 All sera were heat inactivated at 56 C for 45 min. Two-fold dilutions of sera were made in D-MEM, and 50-µ1 aliquots were added to wells of microtiter plates.' Virus was diluted to 300 TCID 50 , 50 µ1 was added to microplate wells, and the mixture was incubated at 37 C for 45 min. A suspension of approximately 2 x 10 4 MDBK cells in 50 µ1 of growth medium was added and incubated at 37 C for 48 hr. Microplates were fixed in 10% formalin and stained in 1% crystal violet. Titers represent the geometric mean titer of 5 wells, rounded to the nearest dilution.
Buffers and reagents. The following buffers were used for the isolation of PRV nucleocapsids. Cell lysis (CL) buffer consisted of 150 mM NaCl, 2 mM MgCl 2 , 10 mM Tris, pH 7.5, and 1% Nonidet P-40. Nuclei disruption (ND) buffer consisted of CL buffer containing 1% sodium deoxycholate. Protease inhibitor cocktail consisted of 1 mM 1, 10-phenanthroline, d 1 mM benzamidine, d 50 µM phenylmethylsulfonyl fluoride, d 50 µM sodium metabisulfite, d 20 µg/ml leupeptin d 50 µg/ml ovomucoid trypsin inhibitor, d 50 µg/ml soybean trypsin inhibitor, d and 50 µg/ml aprotinin. d The following buffers and reagents were used in the ELISA. Antigen coating (AC) buffer was 100 mM sodium carbonate and 100 mM sodium bicarbonate, pH 9.6. Blocking buffer consisted of AC buffer containing 2% gelatin. Serum dilution (SD) buffer consisted of 150 mM NaCl, 10 mM ethylenediaminetetraacetic acid, 0.05% Tween 20, 50 mM Tris, pH 7.4, and 1% gelatin. Wash buffer was 150 mM NaCl, 50 mM Tris, pH 7.4, and 0.5% Tween 20. Goat anti-porcine IgG(H+L) conjugated with horseradish peroxidase e and 2,2'-azinodi-[3-ethyl-benzthiazoline sulfonate] (ATBS) e enzyme substrate solutions were prepared and used according to manufacturer's directions. The following buffers were used in radioimmunoprecipitation and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Radioimmunoprecipitation buffer consisted of 10 mM Tris, pH 7.4, containing 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS. Sample preparation buffer for SDS-PAGE consisted of 2% SDS, 4% 2-mercaptoethanol, 0.05% bromophenol blue, and 50% glycerol in 500 mM Tris, pH 6.8.
PRV subunit vaccine preparation. An envelope glycopro-tein-based PRV subunit vaccine was prepared as previously described. 13 The vaccine consisted of PRV envelope glycoproteins that were isolated from Triton X-100-solubilized virus-infected cells by lectin affinity chromatography using Lens culnaris agglutinin covalently linked to agarose beads. f Appropriate protein concentrations of affinity-purified glycoproteins were emulsified in incomplete Freund's adjuvant and used as vaccine.
PRV nucleocapsid isozation. Nonenveloped PRV nucleocapsids were isolated using a modification of a previously described method. 12, 18 Approximately 10 9 MDBK cells were infected at a multiplicity of 5 with PRV strain Be. Infected cells were harvested 12 hr after infection. Infected cells were lysed by resuspension in CL buffer and incubation for 30 min in an ice bath. Infected cell nuclei were isolated from the cell lysate by centrifugation at 1,000 x g, washed twice in CL buffer, and lysed in 10 ml of ND buffer. Nuclear lysates were incubated at 37 C with 50 µg/ml DNaseI d for 2 hr and clarified at 1,000 x g. The supernatant was layered on a 5-45% glycerol gradient and centrifuged at 100,000 x g for 90 min in a Beckman SW41 rotor. The nucleocapsid pellet was resuspended in 2 ml of 10 mM Tris, pH 7.5, containing 100 µl of protease inhibitor cocktail. This preparation was treated for 30 min at 25 C with Lens culnaris agglutinin covalently linked to agarose beads f and was clarified by centrifugation at 1,000 x g to eliminate any potential contaminating enveloped virus or envelope components. The purity of the nucleocapsids was conformed by electron microscopic examination of 5 negatively stained aliquots of the preparation. No enveloped virions or envelope remnants were found. Purified nucleocapsids were aliquoted and stored at -70 C.
Enzyme-linked immunosorbent assay. Ninety-six well microplatesg were coated with antigen by adding 100 µ1 of AC buffer containing 2 µg of nucleocapsid antigen/ml and incubated overnight at 4 C. All wells were blocked with 200 µ1/well of blocking buffer for 2 hr at 37 C. Test serums were diluted 1:50 in SD buffer. Fifty microliters of diluted serum was added per test well and allowed to react for 20 min at 37 C. All wells were washed 5 times with 200 µ1 of wash buffer. Two hundred microliters of optimally diluted goat anti-porcine IgG(H + L) conjugated to horseradish peroxidase was then added to each well and allowed to react at 37 C for 45 min. All wells were washed as above. Enzyme substrate, ABTS, was added and allowed to react for 30 min before reading. The optical density (OD) of the reaction mixtures was determined at 405 nm with a kinetic microplate reader. h Each reported value represents the mean of 4 replications.
Baseline positive/negative ELISA ODs were determined by testing sera collected from 28 certified PRV-negative pigs. The mean OD of these sera was 0.048 ± 0.025. The range of negative values was 0.010-0.110. Accordingly, the minimum positive threshold was set at 0.200. The maximum negative value was set at 0.110 and all values in between were considered suspect. The commercially available PRV screening ELISA was used according to the manufacturer's directions. i Radioimmunoprecipitation and SDS-PAGE. Purified nucleocapsid protein was labeled with 125 I-sodium iodide using a commercially available kit. j Radioimmunoprecipitation and SDS-PAGE were performed as previously described 4, 20 Approximately 5 x 10 5 were dried under vacuum and exposed to film 1 at -70 C overnight. tion (i.e., sults indicated that the NC-ELISA was not as sensitive congestion, inappetence, as the commercial ELISA in detecting early antibody and depression). Antibody was first detected between days 7 and 14 postchallenge (p.c.) by the commercial ELISA and beresponses to experimental PRV infection of nonvac-tween days 14 and 21 by the NC-ELISA (Table I) . Thereafter, PRV-specific antibody was detected by both cinated pigs. However, the NC-ELISA was as sensitive ELISAs through the end of the experiment. These reas the commercial ELISA after day 14 p.c.
Evaluation of the NC-ELISA. The efficacy of the NC-ELISA was evaluated by comparing its ability to detect PRV infection in experimentally and naturally infected pigs to that of a commercially available ELISA. A total of 28 sera were collected over a 7-wk period from 5 nonvaccinated pigs that were experimentally infected intranasally with 10 4 PFU of virus. Twenty-four field sera were collected through the Iowa State University Veterinary Diagnostic Lab from pigs of herds in which PRV was circulating. The PRV vaccination histories of these pigs were not available. Twenty of these sera had SN titers ranging from 1:2 to 1:64. Four of these field sera did not have detectable SN antibodies. The potential usefulness of the NC-ELISA for detecting infection in subunitvaccinated pigs was also evaluated. Ten weanling pigs were vaccinated with 3 subcutaneous doses of subunit vaccine (1 x 100 µg and 2 x 50 µg of vaccine protein) in Freund's incomplete adjuvant at 21 -day intervals. Serum neutralizing titers in these pigs ranged from 1:4 to 1:32 immediately prior to virus challenge. All pigs were challenged intranasally with 10 2.3 PFU of virus 3 wk after the last vaccine dose and were monitored for PRV nucleocapsid protein-specific antibody periodically for 113 days.
Results

Detection of PRV antibody in experimentally infected
pigs. The PRV-specific antibody response of all experimentally infected pigs was monitored by the commercial ELISA and NC-ELISA periodically throughout the 42-day test period. Following virus challenge, all pigs showed clinical signs indicative of PRV infec-
Detection of PRV antibody in naturally infected pigs.
Sera were collected from 24 pigs from PRV-infected herds. Each serum was analyzed by the SN test, the commercial ELISA, and the NC-ELISA for PRV-specific antibody. Pseudorabies-specific antibody was detected in 20 pigs by all 3 assays and in 23 pigs by the NC-ELISA ( Table 2) . No antibody was detected in 1 of the 24 pigs. The reactivity of the 3 sera that tested positive only by the NC-ELISA was further analyzed by radioimmunoprecipitation using 125 I-labeled PRV nucleocapsid protein. (Fig. 1) . The molecular masses of the immunoprecipitated proteins were in close agreement with previously reported PRV nucleocapsid fraction values. 5, 18 These results provide evidence that an ELISA utilizing nucleocapsid protein can detect PRV infection in pigs that are undetected by the both the SN test and the commercial ELISA.
Detection of nucleocapsid protein-specific antibody in virus-infected subunit-vaccinated pigs.
We also tested the feasibility of using nucleocapsid protein to detect virus infection in 10 pigs that had been immunized with PRV envelope glycoprotein subunit vaccine. The antibody response of the 10 subunit-vaccinated pigs to nucleocapsid protein is summarized in Fig. 2 . The mean OD values remained below the positive threshold prior to challenge but increased dramatically following virus exposure. Antibody levels reached maximum levels by day 32 p.c. Antibody levels decreased thereafter but still remained well above the positive threshold on day 113 p.c. These results demonstrate the compatibility of the NC-ELISA with PRV envelope glycoprotein subunit vaccine.
Discussion
The identification of PRV-vaccinated pigs that have been infected with field strains of PRV is of paramount importance in controlling the spread of pseudorabies. The current approach to vaccination centers on the use of avirulent deletion mutant viruses whereby genes encoding 1 or more viral proteins are deleted using recombinant DNA methodology. Although deletion mutant vaccines have been efficacious, recent studies have shown that in vivo recombination between modified-live deletion mutant vaccines and virulent challenge virus does occur, 6, 7 possibly resulting in the emergence of virulent marker-negative strains of PRV in the field. If the risk of in vivo recombination of modified-live deletion mutant vaccines with virulent field virus poses a threat to national PRV eradication efforts, this approach should be further evaluated and modified. In this study, we evaluated PRV nucleocapsid protein as an ELISA diagnostic antigen. The suitability of PRV nucleocapsid protein in an ELISA was first determined by comparing its efficacy to that of a standard commercially available PRV screening ELISA. Subsequently, we evaluated the potential of the NC-ELISA for use as a differential diagnostic test for pigs immunized with a PRV envelope glycoprotein subunit vaccine.
The NC-ELISA was compared with a commercially available ELISA for the ability to detect PRV-specific antibody in experimentally infected and naturally exposed pigs. There was 100% agreement between both ELISAs in both groups of pigs, with 2 exceptions. Antibody was detected at least 1 week earlier by the commercial ELISA in experimentally infected pigs (Table  1) . However, the SN test and the commercial ELISA failed to detect antibody in 3 of 24 naturally infected pigs that were positive by the NC-ELISA ( Table 2 ). The NC-ELISA reactions -of these 3 pigs were verified by radioimmunoprecipitation ( Fig. 1) . We recognize the possibility that these 3 sera may have contained cross-reacting antibody induced by porcine cytomeg-alovirus. The antigenic cross-relationship of PRV to porcine cytomegalovirus is not known. 12 The earlier detection of antibody by the commercial ELISA may have been due to differences in the antigen composition of the 2 assays. The antigen of the commercial screening assay is a mixture of PRV proteins, including the envelope glycoproteins. In contrast, the antigen of the NC-ELISA consists of highly purified nonenveloped solubilized PRV nucleocapsids. Earlier detection of antibody by the commercial ELISA may also be a reflection of the kinetics of the porcine immune response to different PRV proteins. Several investigators have demonstrated that the SN antibodies that are specific for envelope glycoproteins are usually detectable within the first 7 days after infection. 5, 9, 13 We have likewise shown in previous studies that SN antibodies appear between 4 and 7 days after infection 10, 13 Earlier studies have also demonstrated that antibodies to nucleocapsid proteins were not readily detected until day 14 p.c. 11 The long duration of nucleocapsid-specific antibody makes the NC-ELISA ideal for detecting PRV infections in PRV control programs. The ability of the NC-ELISA to detect PRV infection in the absence of detectable SN antibody was illustrated in the current study by the detection of PRV-specific antibody in the 3 naturally exposed pigs.
The potential of the NC-ELISA as a differential diagnostic test was demonstrated in 10 pigs immunized with a lectin-purified glycoprotein subunit vaccine. Nucleocapsid-specific antibody was first detected in all pigs between days 7 and 21 following nasal challenge with a low dose (10 2.3 PFU) of virulent PRV. Antibody continued to be detected through day 113 p.c., when the experiment was terminated (Fig. 2) . These results are particularly meaningful because the antibody response of vaccinated pigs to a low challenge dose of virus is more difficult to detect than the response to a high virus dose. 10 The low virus challenge dose is also a better reflection of natural exposure among vaccinated pigs because immunized pigs shed less virus than nonimmunized pigs. 20 In this study, the mean NC-ELISA OD rose slightly following subunit vaccine administration. This slight rise was probably not due to contamination of the nucleocapsid antigen with envelope glycoprotein or contamination of the subunit vaccine with nucleocapsid protein. If either preparation were significantly contaminated with the other, the administration of 3 vaccine doses over a 63-day period would have resulted in a more dramatic rise in NC-ELISA OD. Additionally, the NC-ELISA appeared to be detecting a primary response-to nucleocapsid antigen following virus challenge, with a rise to peak OD occurring between 7 and 21 days p.c.
The NC-ELISA can be used for the detection of PRV infection in vaccinated and nonvaccinated pigs. A major advantage of the NC-ELISA is its ability to identify infected pigs that may go undetected if tested with ELISAs based predominantly on glycoprotein antigens. A potential disadvantage of the NC-ELISA is its apparent inability to consistently detect PRV infections during the first 2 weeks after exposure. Furthermore, a PRV nucleocapsid-based ELISA such as that described here may be a significant tool in the ongoing national eradication program. The NC-ELISA may also be valuable for long-term herd monitoring that will follow a successful eradication effort.
